PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

Jan 08, 2013, 07:49 ET from Reportlinker

NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

http://www.reportlinker.com/p01080112/PharmaPoint-Rheumatoid-Arthritis---United-Kingdom-Drug-Forecast-and-Market-Analysis-Event-Driven-Update.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

Summary GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

UK physicians surveyed for this report typically follow guidelines such as NICE or BSR (British Society for Rheumatology), but also follow their own clinical experience as no two patients are the same. In the UK, about 65% of patient referrals at any stage come from PCPs. As in the US, most people seeking treatment are 55 years and older; however within this age group, males outnumber females by a small margin compared with the younger age groups.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in the United Kingdom including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in United Kingdom from 2011 to 2022.- Analysis of the impact of key events as well the drivers and restraints affecting the United Kingdom rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in the United Kingdom- Obtain sales forecast from 2011-2022 in the United Kingdom1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Introduction 102.1 Catalyst 102.2 Related Reports 113 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 133.1.3 Prognosis 163.1.4 Quality of Life 163.2 Symptoms 174 Disease Management 184.1 Treatment Overview 214.2 UK 244.2.1 Diagnosis 244.2.2 Clinical Practice 245 Competitive Assessment 265.1 Overview 265.2 Strategic Competitor Assessment 265.3 Product Profiles - Major Brands 275.3.1 Enbrel (etanercept) 275.3.2 Humira (adalimumab) 335.3.3 Remicade (infliximab) 365.3.4 Simponi (golimumab) 405.3.5 Cimzia (certolizumab pegol) 445.3.6 Orencia (abatacept) 475.3.7 Actemra/RoActemra (tocilizumab) 515.3.8 Rituxan/MabThera (rituximab) 555.3.9 Methotrexate Sodium (numerous generic names) 595.3.10 DMARDs 626 Opportunity and Unmet Need 636.1 Overview 636.2 Unmet Needs 646.2.1 More rheumatologists in the field and physician knowledge of the disease 646.2.2 More cost-effective therapies through oral formulation and biosimilars 646.2.3 The development of predictive tests and discovery of biomarkers 646.2.4 The discovery of curative therapies 646.2.5 Improved drug safety and efficacy profiles 656.3 Gap Analysis 656.4 Opportunities 666.4.1 Predictive Tools for Diagnosis and Treatment 666.4.2 Target Specificity 667 Pipeline Assessment 677.1 Overview 677.2 Promising Drugs in Clinical Development 687.2.1 Tofacitinib (CP-690550) 697.2.2 Tabalumab (LY2127399) 767.2.3 Fostamatinib (previously R788) 797.2.4 RAVAX 837.2.5 Secukinumab (AIN457) 877.2.6 Masitinib (AB101) 917.2.7 Baricitinib (formerly LY3009104/INCB28050) 967.2.8 Sarilumab (REGN88/SAR153191) 1007.2.9 Sirukumab (CNTO 136) 1038 Market Outlook 1068.1 United Kingdom 1068.1.1 Forecast 1068.1.2 Key Events 1098.1.3 Drivers and Barriers 1099 Appendix 1129.1 Abbreviations 1129.2 Bibliography 1149.3 Methodology 1229.4 Forecasting Methodology 1229.4.1 Diagnosed Rheumatoid Arthritis Patients 1229.4.2 Percent Drug-treated Patients 1239.4.3 Drugs Included in Each Therapeutic Class 1239.4.4 Launch and Patent Expiry Dates 1249.4.5 General Pricing Assumptions 1249.4.6 Individual Drug Assumptions 1259.4.7 Generic Erosion 1319.4.8 Pricing of Pipeline agents 1319.5 Physicians and Specialists Included in this Study 1329.6 Primary Research - Prescriber Survey 1329.7 About the Authors 1339.7.1 Analysts 1339.7.2 Global Head of Healthcare 1349.8 About GlobalData 1359.9 Contact Us 1359.10 Disclaimer 135

List of Tables 1.1 List of Tables

Table 1: Symptoms of Rheumatoid Arthritis 17

Table 2: Treatment Guidelines for Rheumatoid Arthritis 21

Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 23

Table 4: Treatment Guidelines for Rheumatoid Arthritis 27

Table 5: Product Profile - Enbrel 28

Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers 29

Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall 30

Table 8: Enbrel SWOT Analysis, 2012 32

Table 9: Product Profile - Humira 33

Table 10: Humira SWOT Analysis, 2012 35

Table 11: Product Profile - Remicade 37

Table 12: Remicade SWOT Analysis, 2012 39

Table 13: Product Profile - Simponi 41

Table 14: Simponi SWOT Analysis, 2012 43

Table 15: Product Profile - Cimzia 45

Table 16: Cimzia SWOT Analysis, 2012 47

Table 17: Product Profile - Orencia 48

Table 18: Orencia SWOT Analysis, 2012 50

Table 19: Product Profile - Actemra/RoActemra 52

Table 20: Actemra/RoActemra SWOT Analysis, 2012 54

Table 21: Product Profile - Rituxan 56

Table 22: Rituxan SWOT Analysis, 2012 58

Table 23: Product Profile - Methotrexate 60

Table 24: Methotrexate SWOT Analysis, 2012 61

Table 25: Summary of Minor Therapeutic Classes, 2012 62

Table 26: Overall Unmet Needs - Current Level of Attainment 63

Table 27: Clinical Unmet Needs - Gap Analysis, 2012 66

Table 28: Rheumatoid Arthritis - Phase Pipeline, 2012 68

Table 29: Comparison of Therapeutic Classes in Development for RA, 2012 69

Table 30: Product Profile - Tofacitinib 70

Table 31: Clinical Trial Locations by Country for Tofacitinib 71

Table 32: ORAL Standard ACR 20 Responses for Tofacitinib vs. Placebo vs. Humira at Month 6 71

Table 33: ORAL Step ACR 20, 50, 70 Responses for Tofacitinib vs. Placebo at Month Six 72

Table 34: Efficacy Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 72

Table 35: Safety Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 73

Table 36: Tofacitinib Clinical Trial Mortalities as of September 29, 2011 74

Table 37: Tofacitinib SWOT Analysis, 2012 75

Table 38: Product Profile - Tabalumab 76

Table 39: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 77

Table 40: Tabalumab SWOT Analysis, 2012 78

Table 41: Product Profile - Fostamatinib 79

Table 42: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three 80

Table 43: Fostamatinib SWOT Analysis, 2012 82

Table 44: Product Profile - RAVAX 83

Table 45: RAVAX SWOT Analysis, 2012 86

Table 46: Product Profile - Secukinumab 87

Table 47: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 88

Table 48: Secukinumab SWOT Analysis, 2012 90

Table 49: Product Profile - Masitinib 91

Table 50: ACR Responses for Masitinib in the ITT Population (12 Weeks) 92

Table 51: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 93

Table 52: Masitinib SWOT Analysis, 2012 95

Table 53: Product Profile - Baricitinib 96

Table 54: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12 97

Table 55: Safety of 4 and 8mg Baricitinib at Week 12 98

Table 56: Laboratory Values of 4 and 8mg Baricitinib at Week 12 98

Table 57: Baricitinib SWOT Analysis, 2012 99

Table 58: Product Profile - Sarilumab 100

Table 59: MOBILITY Study Results for Sarilumab at Week 12 101

Table 60: Sarilumab SWOT Analysis, 2012 102

Table 61: Product Profile - Sirukumab 103

Table 62: Sirukumab SWOT Analysis, 2012 105

Table 63: Sales Forecasts ($m) for Rheumatoid Arthritis in the United Kingdom 107

Table 64: Key Events Impacting Sales for Rheumatoid Arthritis in the United Kingdom, 2012 109

Table 65: Rheumatoid Arthritis Market - Drivers and Barriers in the United Kingdom, 2012 109

Table 66: Key Launch Dates 124

Table 67: Key Patent Expiries 124

Table 68: Physicians Surveyed, By Country 132

List of Figures 1.2 List of Figures

Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 13

Figure 2: Rheumatoid Arthritis Biologic Drug Targets 15

Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System 19

Figure 4: Severity of Rheumatoid Arthritis 20

Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations* 22

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 68

Figure 7: Sales for Rheumatoid Arthritis in the United Kingdom by Drug Class 108

To order this report:Pathology Industry: PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com